Plasma	plasma	O	O	O	O
and	and	O	O	O	O
urinary	urinary	O	O	O	O
lipids	lipids	O	O	O	O
and	and	O	O	O	O
lipoproteins	lipoproteins	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
rat	rat	O	O	O	O
by	by	O	O	O	O
puromycin	puromycin	CHEMICALS	O	OTHERS	I
aminonucleoside	aminonucleoside	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

This	this	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
undertaken	undertaken	O	O	O	O
to	to	O	O	O	O
ascertain	ascertain	O	O	O	O
whether	whether	O	O	O	O
the	the	O	O	O	O
alterations	alterations	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
lipoproteins	lipoproteins	O	O	O	O
found	found	O	O	O	O
in	in	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
induced	induced	O	O	O	O
by	by	O	O	O	O
puromycin	puromycin	CHEMICALS	O	OTHERS	I
aminonucleoside	aminonucleoside	CHEMICALS	O	OTHERS	I
were	were	O	O	O	O
due	due	O	O	O	O
to	to	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
per	per	O	O	O	O
se	se	O	DISEASE	OTHERS	I
,	,	O	O	O	O
or	or	O	O	O	O
,	,	O	O	O	O
at	at	O	O	O	O
least	least	O	O	O	O
in	in	O	O	O	O
part	part	O	O	O	O
,	,	O	O	O	O
to	to	O	O	O	O
the	the	O	O	O	O
aminonucleoside	aminonucleoside	CHEMICALS	O	OTHERS	I
.	.	O	O	O	O

The	the	O	O	O	O
purpose	purpose	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
present	present	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
to	to	O	O	O	O
investigate	investigate	O	O	O	O
the	the	O	O	O	O
changes	changes	O	O	O	O
in	in	O	O	O	O
plasma	plasma	O	O	O	O
and	and	O	O	O	O
urinary	urinary	O	O	O	O
lipoproteins	lipoproteins	O	O	O	O
during	during	O	O	O	O
the	the	O	O	O	O
administration	administration	O	O	O	O
of	of	O	O	O	O
puromycin	puromycin	CHEMICALS	O	OTHERS	I
aminonucleoside	aminonucleoside	CHEMICALS	O	OTHERS	I
(	(	O	O	O	O
20	20	O	O	O	O
mg/kg	mg/kg	O	O	O	O
for	for	O	O	O	O
7	7	O	O	O	O
days	days	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
the	the	O	O	O	O
subsequent	subsequent	O	O	O	O
development	development	O	O	O	O
of	of	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
syndrome	syndrome	O	DISEASE	OTHERS	I
.	.	O	O	O	O

Since	since	O	O	O	O
massive	massive	O	O	O	O
albuminuria	albuminuria	O	DISEASE	OTHERS	I
occurred	occurred	O	O	O	O
after	after	O	O	O	O
6	6	O	O	O	O
days	days	O	O	O	O
of	of	O	O	O	O
treatment	treatment	O	O	O	O
,	,	O	O	O	O
the	the	O	O	O	O
time-course	time-course	O	O	O	O
study	study	O	O	O	O
was	was	O	O	O	O
divided	divided	O	O	O	O
into	into	O	O	O	O
two	two	O	O	O	O
stages	stages	O	O	O	O
:	:	O	O	O	O
pre-nephrotic	pre-nephrotic	O	O	O	O
stage	stage	O	O	O	O
(	(	O	O	O	O
day	day	O	O	O	O
1	1	O	O	O	O
-	-	O	O	O	O
5	5	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
stage	stage	O	O	O	O
(	(	O	O	O	O
day	day	O	O	O	O
6	6	O	O	O	O
-	-	O	O	O	O
11	11	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
pre-nephrotic	pre-nephrotic	O	O	O	O
stage	stage	O	O	O	O
the	the	O	O	O	O
plasma	plasma	O	O	O	O
level	level	O	O	O	O
of	of	O	O	O	O
fatty	fatty	CHEMICALS	O	OTHERS	I
acids	acids	CHEMICALS	O	OTHERS	I
,	,	O	O	O	O
triacylglycerol	triacylglycerol	O	O	OTHERS	I
and	and	O	O	O	O
VLDL	vldl	O	O	O	O
decreased	decreased	O	O	O	O
while	while	O	O	O	O
that	that	O	O	O	O
of	of	O	O	O	O
phospholipid	phospholipid	O	O	O	O
,	,	O	O	O	O
cholesteryl	cholesteryl	O	O	OTHERS	I
esters	esters	O	O	OTHERS	I
and	and	O	O	O	O
HDL	hdl	O	O	O	O
remained	remained	O	O	O	O
constant	constant	O	O	O	O
.	.	O	O	O	O

Plasma	plasma	O	O	O	O
apolipoprotein	apolipoprotein	O	O	O	O
A-I	a-i	O	O	O	O
tended	tended	O	O	O	O
to	to	O	O	O	O
increase	increase	O	O	O	O
(	(	O	O	O	O
40	40	O	O	O	O
%	%	O	O	O	O
increase	increase	O	O	O	O
at	at	O	O	O	O
day	day	O	O	O	O
5	5	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

At	at	O	O	O	O
the	the	O	O	O	O
beginning	beginning	O	O	O	O
of	of	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
stage	stage	O	O	O	O
(	(	O	O	O	O
day	day	O	O	O	O
6	6	O	O	O	O
)	)	O	O	O	O
the	the	O	O	O	O
concentration	concentration	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
albumin	albumin	O	O	O	O
dropped	dropped	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
very	very	O	O	O	O
low	low	O	O	O	O
level	level	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
that	that	O	O	O	O
of	of	O	O	O	O
apolipoprotein	apolipoprotein	O	O	O	O
A-I	a-i	O	O	O	O
increased	increased	O	O	O	O
abruptly	abruptly	O	O	O	O
(	(	O	O	O	O
4-fold	4-fold	O	O	O	O
increase	increase	O	O	O	O
)	)	O	O	O	O
and	and	O	O	O	O
continued	continued	O	O	O	O
to	to	O	O	O	O
rise	rise	O	O	O	O
,	,	O	O	O	O
although	although	O	O	O	O
less	less	O	O	O	O
steeply	steeply	O	O	O	O
,	,	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
following	following	O	O	O	O
days	days	O	O	O	O
.	.	O	O	O	O

The	the	O	O	O	O
plasma	plasma	O	O	O	O
concentration	concentration	O	O	O	O
of	of	O	O	O	O
HDL	hdl	O	O	O	O
followed	followed	O	O	O	O
the	the	O	O	O	O
same	same	O	O	O	O
pattern	pattern	O	O	O	O
.	.	O	O	O	O

Plasma	plasma	O	O	O	O
VLDL	vldl	O	O	O	O
and	and	O	O	O	O
LDL	ldl	O	O	O	O
increased	increased	O	O	O	O
at	at	O	O	O	O
a	a	O	O	O	O
later	later	O	O	O	O
stage	stage	O	O	O	O
(	(	O	O	O	O
day	day	O	O	O	O
9	9	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

Plasma	plasma	O	O	O	O
apolipoprotein	apolipoprotein	O	O	O	O
A-I	a-i	O	O	O	O
was	was	O	O	O	O
found	found	O	O	O	O
not	not	O	O	O	O
only	only	O	O	O	O
in	in	O	O	O	O
HDL	hdl	O	O	O	O
(	(	O	O	O	O
1.063	1.063	O	O	O	O
-	-	O	O	O	O
1.210	1.210	O	O	O	O
g/ml	g/ml	O	O	O	O
)	)	O	O	O	O
but	but	O	O	O	O
also	also	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
LDL	ldl	O	O	O	O
density	density	O	O	O	O
class	class	O	O	O	O
(	(	O	O	O	O
1.025	1.025	O	O	O	O
-	-	O	O	O	O
1.050	1.050	O	O	O	O
g/ml	g/ml	O	O	O	O
)	)	O	O	O	O
.	.	O	O	O	O

In	in	O	O	O	O
the	the	O	O	O	O
pre-nephrotic	pre-nephrotic	O	O	O	O
stage	stage	O	O	O	O
lipoproteinuria	lipoproteinuria	O	O	O	O
was	was	O	O	O	O
negligible	negligible	O	O	O	O
,	,	O	O	O	O
while	while	O	O	O	O
in	in	O	O	O	O
the	the	O	O	O	O
early	early	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
stage	stage	O	O	O	O
the	the	O	O	O	O
urinary	urinary	O	O	O	O
loss	loss	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
lipoproteins	lipoproteins	O	O	O	O
consisted	consisted	O	O	O	O
mainly	mainly	O	O	O	O
of	of	O	O	O	O
HDL	hdl	O	O	O	O
.	.	O	O	O	O

These	these	O	O	O	O
observations	observations	O	O	O	O
indicate	indicate	O	O	O	O
that	that	O	O	O	O
puromycin	puromycin	CHEMICALS	O	OTHERS	I
aminonucleoside	aminonucleoside	CHEMICALS	O	OTHERS	I
alters	alters	O	O	O	O
plasma	plasma	O	O	O	O
lipoproteins	lipoproteins	O	O	O	O
by	by	O	O	O	O
lowering	lowering	O	O	O	O
VLDL	vldl	O	O	O	O
and	and	O	O	O	O
increasing	increasing	O	O	O	O
HDL	hdl	O	O	O	O
.	.	O	O	O	O

It	it	O	O	O	O
is	is	O	O	O	O
likely	likely	O	O	O	O
that	that	O	O	O	O
the	the	O	O	O	O
early	early	O	O	O	O
and	and	O	O	O	O
striking	striking	O	O	O	O
increase	increase	O	O	O	O
of	of	O	O	O	O
plasma	plasma	O	O	O	O
HDL	hdl	O	O	O	O
found	found	O	O	O	O
in	in	O	O	O	O
nephrotic	nephrotic	O	DISEASE	OTHERS	I
rats	rats	O	O	O	O
is	is	O	O	O	O
related	related	O	O	O	O
to	to	O	O	O	O
a	a	O	O	O	O
direct	direct	O	O	O	O
effect	effect	O	O	O	O
of	of	O	O	O	O
the	the	O	O	O	O
drug	drug	O	O	O	O
on	on	O	O	O	O
HDL	hdl	O	O	O	O
metabolism	metabolism	O	O	O	O
.	.	O	O	O	O

